Immunomedics Inc. announced that it has begun advancedclinical trials in Europe on six of its monoclonal antibody-baseddiagnostics and one therapeutic product. The imaging agents,which incorporate the radioisotope technetium-99m, includeImmuRAID-CEA.
Immunomedics (NASDAQ:IMMU) filed for marketing approvalin Europe for ImmuRAID-CEA for detecting colorectal cancer inMarch.
The trials will be conducted in England, France, Germany,Switzerland, Italy and Austria, and will test ImmuRAID-CEAfor its ability to detect lung and breast cancers. Otherdiagnostics slated for the European trials include ImmuRAID-MN3 for infectious diseases, ImmuRAID-AFP for liver cancer,and ImmuRAID-LL2 for B-cell lymphomas. These products areeither already in Phase III clinicals in the U.S. or will be nextyear, the Morris Plains, N.J., company said.
And the therapeutic, ImmuRAIT-22 will be in trials fortreating B-cell lymphoma. It is already in Phase I/II trials inthe U.S. -- Jennifer Van Brunt
(c) 1997 American Health Consultants. All rights reserved.